Trial Profile
A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients with cancer or Leptomeningeal Metastases.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Pemetrexed (Primary)
- Indications Cancer metastases; Haematological malignancies; Lymphoma; Solid tumours
- Focus Biomarker; Pharmacokinetics; Therapeutic Use
- 03 Sep 2021 Status changed from active, no longer recruiting to completed.
- 16 Aug 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 16 Aug 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.